Field Medical | $35,000,000 | (Jul 2, 2025)
Syntis Bio | $38,000,000 | (Jul 2, 2025)
Deeto | $12,500,000 | (Jul 2, 2025)
Certified by Founder
Lodge
AusperBio
start up
United States
- San Mateo, California
- 16/07/2024
- Series A
- $37,000,000
AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to advancing oligonucleotide and targeted delivery technologies for transformative therapies, with an initial focus on curing chronic hepatitis B. The company has developed a proprietary Med-OligoTM ASO platform with novel insights into ASO design and capabilities to substantially enhance the current ASO therapeutics. Combining with efficient targeted delivery conjugation technologies, the modular Med-OligosTM Platform empowers ASO therapeutics to treat broad viral infections, metabolic conditions, genetic disorders, and immune diseases.
- Industry Biotechnology Research
- Website https://www.ausperbio.com/
- LinkedIn https://www.linkedin.com/company/ausperbio/
Talon.One | $135,000,000 | (Jul 2, 2025)
Bonx | $8,600,000 | (Jul 2, 2025)
Civ Robotics | $7,500,000 | (Jul 2, 2025)
Metafide | $3,275,000 | (Jul 2, 2025)
Genesis AI | $105,000,000 | (Jul 2, 2025)
Emerald AI | $24,500,000 | (Jul 2, 2025)
zango | $4,800,000 | (Jul 2, 2025)
Clearspeed | $60,000,000 | (Jul 1, 2025)
Foresight(US) | $5,500,000 | (Jul 1, 2025)